Buzz, I would love it if you are correct, but isn't it a possibility that the "short" activity reported is that of market makers providing liquidity rather than investors actually taking a short position?
DMRJ doesn't need to short. They can convert and sell into the market. And selling a share converted at $0.08 for $1.38 makes a lot of sense.
Look at the reported shares outstanding. In its September 29th 10-K filing, Implant reported 66,507,625 shares outstanding (which included 2.65 million of shares DMRJ converted in September). On October 23rd, they filed a 10-KA and reported 68,938,120 shares of outstanding. Because no Form 4’s reporting option exercises have been filed, the only explanation is DMRJ.